{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fayad L"],"funding":["NCI NIH HHS"],"pagination":["573-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4878046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(5)"],"pubmed_abstract":["<h4>Purpose</h4>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL).<h4>Patients and methods</h4>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.<h4>Results</h4>In all, 118 "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab."],"pmcid":["PMC4878046"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Rohatiner A","Hess G","Johnson P","Kneissl M","Hua SY","Smith MR","Advani A","Luu KT","Verhoef G","Kaufman JL","Dang NH","Foran J","Offner F","Czuczman M","Durrant S","Coiffier B","Vandendries E","Fayad L","Gine E","Boni J"],"additional_accession":[]},"is_claimable":false,"name":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.","description":"<h4>Purpose</h4>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL).<h4>Patients and methods</h4>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.<h4>Results</h4>In all, 118 ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Feb","modification":"2025-04-19T12:31:21.6Z","creation":"2019-03-27T02:14:24Z"},"accession":"S-EPMC4878046","cross_references":{"pubmed":["23295790"],"doi":["10.1200/JCO.2012.42.7211","10.1200/jco.2012.42.7211"]}}